Xiaoshan Wei[Author] - Search Results

Year	Number of Results
2017	1
2018	2
2019	2
2020	8
2021	5
2022	3
2023	7
2024	0

1

C1q⁺ tumor-associated macrophages contribute to immunosuppression through fatty acid metabolic reprogramming in malignant pleural effusion.

Zhang S, Peng W, Wang H, Xiang X, Ye L, Wei X, Wang Z, Xue Q, Chen L, Su Y, Zhou Q. Zhang S, et al. Among authors: wei x. J Immunother Cancer. 2023 Aug;11(8):e007441. doi: 10.1136/jitc-2023-007441. J Immunother Cancer. 2023. PMID: 37604643 Free PMC article.

2

Targeting CXCL9/10/11-CXCR3 axis: an important component of tumor-promoting and antitumor immunity.

Pan M, Wei X, Xiang X, Liu Y, Zhou Q, Yang W. Pan M, et al. Among authors: wei x. Clin Transl Oncol. 2023 Aug;25(8):2306-2320. doi: 10.1007/s12094-023-03126-4. Epub 2023 Apr 19. Clin Transl Oncol. 2023. PMID: 37076663 Review.

3

Promising immunotherapeutic targets in lung cancer based on single-cell RNA sequencing.

Xue Q, Peng W, Zhang S, Wei X, Ye L, Wang Z, Xiang X, Zhang P, Zhou Q. Xue Q, et al. Among authors: wei x. Front Immunol. 2023 Apr 28;14:1148061. doi: 10.3389/fimmu.2023.1148061. eCollection 2023. Front Immunol. 2023. PMID: 37187731 Free PMC article. Review.

4

Interferon-α2b Treatment for COVID-19.

Zhou Q, Chen V, Shannon CP, Wei XS, Xiang X, Wang X, Wang ZH, Tebbutt SJ, Kollmann TR, Fish EN. Zhou Q, et al. Front Immunol. 2020 May 15;11:1061. doi: 10.3389/fimmu.2020.01061. eCollection 2020. Front Immunol. 2020. PMID: 32574262 Free PMC article. Clinical Trial.

5

Medical thoracoscopy in China-the present status and the future.

Liu JY, Xiong L, Zhang M, Shuai SY, Wei XS, Ye LL, Zhou Q. Liu JY, et al. J Thorac Dis. 2017 Feb;9(2):406-413. doi: 10.21037/jtd.2017.02.39. J Thorac Dis. 2017. PMID: 28275489 Free PMC article. Review.

6

Corrigendum: Interferon-α2b Treatment for COVID-19.

Zhou Q, Chen V, Shannon CP, Wei XS, Xiang X, Wang X, Wang ZH, Tebbutt SJ, Kollmann TR, Fish EN. Zhou Q, et al. Front Immunol. 2020 Oct 27;11:615275. doi: 10.3389/fimmu.2020.615275. eCollection 2020. Front Immunol. 2020. PMID: 33193462 Free PMC article.

7

Lutein inhibits tumor progression through the ATR/Chk1/p53 signaling pathway in non-small cell lung cancer.

Zhang SY, Lu YY, He XL, Su Y, Hu F, Wei XS, Pan MJ, Zhou Q, Yang WB. Zhang SY, et al. Phytother Res. 2023 Apr;37(4):1260-1273. doi: 10.1002/ptr.7682. Epub 2022 Nov 21. Phytother Res. 2023. PMID: 37041670

8

Altered phenotypic and metabolic characteristics of FOXP3⁺CD3⁺CD56⁺ natural killer T (NKT)-like cells in human malignant pleural effusion.

Wang ZH, Zhang P, Peng WB, Ye LL, Xiang X, Wei XS, Niu YR, Zhang SY, Xue QQ, Wang HL, Zhou Q. Wang ZH, et al. Oncoimmunology. 2022 Dec 22;12(1):2160558. doi: 10.1080/2162402X.2022.2160558. eCollection 2023. Oncoimmunology. 2022. PMID: 36567801 Free PMC article.

9

Co-infection of SARS-COV-2 and Influenza A Virus: A Case Series and Fast Review.

Xiang X, Wang ZH, Ye LL, He XL, Wei XS, Ma YL, Li H, Chen L, Wang XR, Zhou Q. Xiang X, et al. Curr Med Sci. 2021 Feb;41(1):51-57. doi: 10.1007/s11596-021-2317-2. Epub 2021 Feb 13. Curr Med Sci. 2021. PMID: 33582905 Free PMC article. Review.

10

The Significance of Tumor Necrosis Factor Receptor Type II in CD8⁺ Regulatory T Cells and CD8⁺ Effector T Cells.

Ye LL, Wei XS, Zhang M, Niu YR, Zhou Q. Ye LL, et al. Front Immunol. 2018 Mar 22;9:583. doi: 10.3389/fimmu.2018.00583. eCollection 2018. Front Immunol. 2018. PMID: 29623079 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

25 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year